A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer.
By P. Goss, J. Ingle, S. Martino, N. Robert, H. Muss, M. Piccart, M. Castiglione, D. Tu, L. Shepherd, K. Pritchard and 8 more. New England Journal of Medicine, 2004
1,015 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/c8bbde30cd1cfed0fff15ea76d77079167069da1
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Oncology
Citations in the corpus
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 (2013, neutral): “17 study [85].”
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, background): “In patients becoming postmenopausal during the first 5 years of tamoxifen, a switch to letrozole, an aromatase inhibitor (AI), seems to be particularly beneficial [99].”
- Adherence to Adjuvant Hormonal Therapy among Breast Cancer Survivors in Clinical Practice: A Systematic Review (2012, positive): “Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, evidence from clinical trials suggests 8–28 % of patients do not complete treatment as recommended [2, 4, 5, 12].”
- A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. (2004, methodology): “Tamoxifen is thought to act 1998; Ellis et al., 2001; Goss et al., 2003), chemotherapeutic agents (Colleoni et al., 2003a), or inhibitors of other signaling pathways, primarily as a competitive inhibitor of estrogen binding to estrogen receptor (ER), and it has no effect on tumor cells lacking such…”
- Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts (2005, background): “The use of anthracyclinebased and taxane-based therapy and more optimal endocrine therapy strategies might alter the distribution of patients, especially moving individuals from type C to type B [37-41], as experienced with the Her-2 status and adjuvant anthracycline therapy [42].”